Amgen battling Pfizer for Celgene bid

Quote








Amgen almost acquired Celgene years and it was a done deal until Roger Permuletter called it off last minute. That was the best time to acquire them and it would have given us Otezla and the whole Revlimid franchise. The reality is Kyprolis is just another protease inhibitor. With so many new agents, Amgen is having a hard time being a MM leader let alone a key player in oncology.

This company has had many chances but is like a young girl who keeps dating assholes when she has perfectly good guys in front of her but can’t see that. That’s why they now need are in desperation mode to grow that top line.
 




anonymous said:
Stop this nonsense. Amgen can’t afford to acquire Celgene. Also, Amgen and Celgene won’t ever agree on merger terms that would be acceptable to Celgene shareholders.
Click to expand...

They said Pfizer couldn’t afford Wyeth and Merck couldn’t do scheerinh plough. When Capital is cheap and Amgen with cash, it’s all possible. Bob Bradway doesn’t know science but he knows M&A and creative deal structures.
 




anonymous said:
They said Pfizer couldn’t afford Wyeth and Merck couldn’t do scheerinh plough. When Capital is cheap and Amgen with cash, it’s all possible. Bob Bradway doesn’t know science but he knows M&A and creative deal structures.
Click to expand...

No amount of creativity can overcome the deficiencies in Amgen’s balance sheet for a 100 billion dollar deal.
 












anonymous said:
Amgen already has too much debt to take on more for such a big transaction as Celgene.
Click to expand...

Borrow money - the increased cash flow would help amgen. The combined org has overlapping sales force so they could add revenue while decreasing cost.

Recent celgene set backs makes it an opportune time for amgen to be aggressive.
 




The recent ozanimod failure is good for amgen as the market cap has diminished greatly. Amgen is doing due diligence to see how long the ozanimod delay and impact to peak share risk will be. They are looking to bid for a takeover and gambling the delay isn’t too long. They could rebuild oncology with Celgene , enhance inflammation and derm with otezla, supplement neuro with ozanimod and build GI with it in time for Humira biosimilar.
 




You are an idiot to be leaking confidential Amgen BD discussions on to an internet message board. Amgen knows who knows what info and they can get law to grill everyone to find you. Don't fuck it up for the rest of us.
 




The key question is whether a 40% premium would be enough to buy Celgene via hostile takeover.

With a market cap of $70B, amgen would could use its cash for $50B and then finance the rest by raising equity. The models are being worked out and the integration assumptions and revenue for each product is part of the Due Dilligence. Amgen is hoping for a $100-110B buyout with a $70B financing.
 








anonymous said:
could this be in the works?
Click to expand...

Amgen trying to circumvent Celgene management by going directly to the board. Celgene management is responding that the Amgen offer is undervaluing the company and the offer premium based on recent lows because of mongerson failure and ozanimod delay is an inferior offer and does not reflect the true value of the pipeline.
 








anonymous said:
Amgen trying to circumvent Celgene management by going directly to the board. Celgene management is responding that the Amgen offer is undervaluing the company and the offer premium based on recent lows because of mongerson failure and ozanimod delay is an inferior offer and does not reflect the true value of the pipeline.
Click to expand...
Going to the board is best possibility to strike a deal.
 












anonymous said:
You guys do know this thread is complete bullshit, right?
Click to expand...


So are you saying Amgen has no interest in Celgene? Given the overlapping therapeutic areas of interest, you are saying it’s no feasible?

Are you saying it’s not well known Amgen needs major M&A? Let’s be honest - to many recent misfires and lack of pricing increase means Amgen needs several major acquisitions or one big one. Acquiring 3-4 mid sized companies and integrating is hell compared to big Celgene acquisition. The cuts are easier and more straightforward.
 








anonymous said:
Looks like Celgene has other plans... https://www.investors.com/news/tech...lion-deal-with-celgene/?src=A00220&yptr=yahoo
Click to expand...


Yeah because an extra $150 million is really going to break the bank for Amgen. If Amgen acquires Celgene, it would be real smart at this point with the low stock price. I mean Celgene just bought Juno for 14 billion right? So that means you get Celgene AND Juno for you're buying price, and with the Celgene market cap at the lowest it's been in 4 years.

Amgen would have to be fools not to try a hostile takeover.
 




Top Bottom
Back
Quote